Mizuho analyst Brett Linzey raised the firm’s price target on Dover to $165 from $155 and keeps a Buy rating on the shares. The analyst views the Q4 results positively with potential upside to numbers should Biopharma demand recover faster.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DOV: